Clinical Trial Update: SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) [Phase 2]

View source ↗

Summary

Phase 2 trial SER-109 vs placebo for preventing recurrent Clostridioides difficile infection has completed, with results posted in 2018. The study was sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• SER-109

Snippet

Sponsor: Seres Therapeutics, Inc. | Conditions: Clostridium Difficile | Phase 2 | Status: COMPLETED | Results posted: 2018-07-26